Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Why Were Investors Going Bonkers For These 4 Stocks On Monday?

Page 1 of 2

In Monday trading news, TeleCommunication Systems Inc. (NASDAQ:TSYS), KaloBios Pharmaceuticals Inc. (NASDAQ:KBIO) and Peabody Energy Corp. (NYSE:BTU) all made big gains on heavy trading volumes following separate merger and sales agreements, while Mallinckrodt Public Ltd. Co. (NYSE:MNK) was sparking positive vibes after growing its net sales during the latest quarter. Let’s look deeper into today’s news as well as look at what the investors from our database think about these stocks.

wireless, telecoms, antenna, tower, broadcasting, station, cellular, building, sky, steel, telephone, technology, equipment, electromagnetic, mobile, architecture, transmitter


Most investors don’t understand hedge funds and indicators that are based on hedge funds’ activities. They ignore hedge funds because of their recent poor performance in the bull market. Our research indicates that hedge funds underperformed because they aren’t 100% long. Hedge fund fees are also very large compared to the returns generated and they reduce the net returns experienced by investors. We uncovered that hedge funds’ long positions actually outperformed the market. For instance the 15 most popular small-cap stocks among funds beat the S&P 500 Index by more than 53 percentage points since the end of August 2012. These stocks returned a cumulative of 102% vs. a 49% gain for the S&P 500 Index (read the details). That’s why we believe investors should pay attention to what hedge funds are buying (rather than what their net returns are).

TeleCommunication Systems Inc. (NASDAQ:TSYS) rallied by 12.53% after striking an agreement that will see the company sell itself for approximately $430.8 million in enterprise value. Comtech Telecommunications Corp. (NASDAQ:CMTL), whose shares dropped by 6.31% on Monday, will acquire TeleCommunication Systems for $5 per share, expecting that the deal will be accretive during the first year as a combined company. The acquisition is expected to bring in approximately $8.0 million in the first year following the closing and $12.0 million in the second year, the companies said.

By the end of September, 12 funds out of the 730 in our database held 19.50% of the outstanding stock of TeleCommunication Systems. Top investor Becker Drapkin Management held 3.38 million shares of the company at the end of September, valued at $11.6 million.

Follow Telecommunication Systems Inc (NASDAQ:TSYS)
Trade (NASDAQ:TSYS) Now!

Meanwhile, 11 funds in our database held 17.10% of Comtech’s outstanding stock on September 30. First Eagle Investment Management held 1.63 million shares of the company valued at $33.5 million.

Follow Comtech Telecommunications Corp (NASDAQ:CMTL)
Trade (NASDAQ:CMTL) Now!

KaloBios Pharmaceuticals Inc. (NASDAQ:KBIO) skyrocketed by another 116.44% after monster trading days on Thursday and Friday of last week that have seen its shares soar by over 1,800%. The biopharmaceutical company, which was in dire straits, sold 70% of its outstanding shares to an investor group led by Turing Pharmaceuticals AG Founder and CEO Martin Shkreli, who will also run KaloBios as its new CEO and Chairman of the Board. KaloBios received at least $3.0 million in equity backing from Shkreli and other investors on top of a $10 million facility for equity financing. The new CEO also expressed positivity regarding KaloBios’ lenzilumab, to treat rare and orphan diseases. “Lenzilumab has particular promise in Chronic Myelomonocytic Leukemia (CMML), a disease with no FDA-approved treatment options and a 3-year overall survival rate of 20%,” Shkreli said.

As of the end of September, Renaissance Technologies held 3.30% of the outstanding stock of KaloBios, valued at $259,000 at that time (now significantly more).

Follow Kalobios Pharmaceuticals Inc (NASDAQ:KBIO)
Trade (NASDAQ:KBIO) Now!
Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!